research Role of EZH2 in Uterine Gland Development
EZH2 is crucial for uterine gland development and female fertility.
Search
for
Sort by
Research
990-1000 / 1000+ resultsresearch The latest options and future agents for treating male hypogonadism
New and future treatments for male hypogonadism include various forms of testosterone therapy and emerging drugs.
research PD23-01 INHIBITOR OF 5A-REDUCTASE TYPES II PROMOTES THE INFILTRATION OF CD8+T CELLS IN BPH TISSUES.
Finasteride increases CD8+ T cells in BPH tissues.
research PD59-09 PHOSPHODIESTERASE INHIBITORS COULD REVERSE THE PROLIFERATION OF BPH EPITHELIAL CELLS INDUCED BY CD8+ T CELLS IN LOW ANDROGEN CONDITION
Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
research Follicular Fluid: A Powerful Tool for the Understanding and Diagnosis of Polycystic Ovary Syndrome
Analyzing follicular fluid can help predict and improve outcomes for women with PCOS undergoing fertility treatments.
research Inhibition of neurosteroid synthesis increases asphyxia-induced brain injury in the late gestation fetal sheep
Reducing neurosteroid levels worsens brain injury in fetal sheep.
research 1 Androgens
Testosterone is made by Leydig cells, is active when not bound to proteins, and works by binding to receptors in muscles and other tissues.
research Finasteride-its impact on sexual function and prostate cancer
Finasteride reduces prostate cancer risk but may affect ejaculatory volume and requires careful consideration for young men.
research SKUTECZNOŚĆ STOSOWANIA STANDARDOWYCH PROTOKOŁÓW KONTROLOWANEJ STYMULACJI JAJNIKÓW ZE SKŁADNIKIEM LH I BEZ NIEGO U PACJENTEK Z OBNIŻONĄ REZERWĄ JAJNIKOWĄ
Using a protocol with LH improves pregnancy rates in patients with low ovarian reserve.
research Response to comments on the Scientific Opinion on the substantiation of a health claim related to spermidine and prolongation of the growing phase (anagen) of the hair cycle pursuant to Article 13(5) of Regulation (EC) No 1924/2006
The EFSA maintained its view that spermidine's effect on hair growth is related to disease treatment and does not meet the health claim criteria.